HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial
Authors:
- Manal AbdelmalekMAManal Abdelmalek
- Jaeduk ChoiJCJaeduk Choi
- Youngmin KimYKYoungmin Kim
- Kyounghee SeoKSKyounghee Seo
- Marcus HompeschMHMarcus Hompesch
- Seungjae BaekSBSeungjae Baek
- 1 August 2020
- journal article
- abstracts
- Published by Elsevier in Journal of Hepatology
- Vol. 73, S124